Corcept Therapeutics Incorporated - Common Stock (NQ:CORT)

Corcept Therapeutics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Corcept Therapeutics Incorporated - CORT

February 25, 2026

From SkyMedia, LLC

Law Offices of Howard G. Smith Encourages Corcept Therapeutics Incorporated (CORT) Shareholders To Inquire About Securities Fraud Class Action

February 25, 2026

From Law Offices of Howard G. Smith

CORT Investors Deadline Alert: Kaplan Fox Announces Corcept Therapeutics, Inc. Securities Class Action Filed - Lead Plaintiff Deadline April 21, 2026

Corcept Therapeutics (NASDAQ:CORT) Stock Falls After Q4 Earnings Miss Estimates ↗

February 24, 2026

Via Chartmill

Topics Earnings

February 25, 2026

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

CORT Investors Deadline Alert: Kaplan Fox Announces Corcept Therapeutics, Inc. Securities Class Action Filed - Lead Plaintiff Deadline April 21, 2026

Topics Lawsuit

February 25, 2026

NEW YORK, NY - February 25, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Corcept Therapeutics, Inc. (“Corcept” or the “Company”)...

Corcept Therapeutics Incorporated Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – CORT

Topics Lawsuit

February 25, 2026

From The DJS Law Group

CORT Stock Slips After-Hours On Weak Q4 Print: Retail Is Watching April FDA Meeting For Relacorilant As Next Catalyst ↗

February 25, 2026

The company guided for $900 million to $1 billion in 2026 revenue.

Via Stocktwits

CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit with the Schall Law Firm

February 24, 2026

From The Schall Law Firm

Corcept Therapeutics Incorporated Securities Fraud Class Action Result of FDA Approval Issues and 50% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

February 24, 2026

From Kahn Swick & Foti, LLC

Biopharma company Corcept Therapeutics (NASDAQ:CORT) fell short of the market’s revenue expectations in Q4 CY2025, but sales rose 11.1% year on year to $202.1 million. Its GAAP profit of $0.20 per...

Corcept (NASDAQ:CORT) Misses Q4 CY2025 Sales Expectations

February 24, 2026

Via StockStory

Topics Artificial Intelligence Supply Chain

Corcept Therapeutics Announces Fourth Quarter and Full-Year 2025 Audited Financial Results, Provides Corporate Update

February 24, 2026

From Corcept Therapeutics Incorporated

Kaplan Fox Encourages Investors of Corcept Therapeutics, Inc. (CORT) to Contact the Firm Before Lead Plaintiff Deadline on April 21, 2026

February 24, 2026

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Kaplan Fox Encourages Investors of Corcept Therapeutics, Inc. (CORT) to Contact the Firm Before Lead Plaintiff Deadline on April 21, 2026

Topics Lawsuit

February 24, 2026

NEW YORK, NY - February 24, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Corcept Therapeutics, Inc. (“Corcept” or the “Company”)...

INVESTOR DEADLINE: Corcept Therapeutics Incorporated Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces

Topics Lawsuit

February 24, 2026

From Robbins Geller Rudman & Dowd LLP

Kaplan Fox Encourages Corcept Therapeutics, Inc. (CORT) Investors to Inquire About Ongoing Investigation

February 24, 2026

NEW YORK, NY - February 24, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Corcept Therapeutics, Inc. (“Corcept” or the “Company”) (NASDAQ:...

Kaplan Fox Encourages Corcept Therapeutics, Inc. (CORT) Investors to Inquire About Ongoing Investigation

February 24, 2026

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Corcept Therapeutics Incorporated (CORT)

February 24, 2026

From Bernstein Liebhard LLP

Corcept Therapeutics Incorporated Securities Fraud Class Action Result of FDA Approval Issues and 50% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

February 23, 2026

From Kahn Swick & Foti, LLC

CORCEPT CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Corcept Therapeutics Incorporated and Encourages Investors to Contact the Firm

February 23, 2026

From Bragar Eagel & Squire

INVESTOR ALERT: Securities Class Action Filed Against Corcept Therapeutics Incorporated – Investors Encouraged to Contact Kirby McInerney LLP

February 23, 2026

From Kirby McInerney LLP

Rosen Law Firm Urges Corcept Therapeutics Incorporated (NASDAQ: CORT) Stockholders to Contact the Firm for Information About Their Rights

February 23, 2026

From The Rosen Law Firm, P.A.

CORCEPT THERAPEUTICS INCORPORATED (CORT) INVESTOR ALERT Investors With Large Losses in Corcept Therapeutics Incorporated Should Contact Bernstein Liebhard LLP To Discuss Their Rights

February 23, 2026

From Bernstein Liebhard LLP

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

CORT Investors Notified of Investigation Into Corcept Therapeutics, Inc. by Kaplan Fox

February 23, 2026

NEW YORK, NY - February 23, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Corcept Therapeutics, Inc. (“Corcept” or the “Company”) (NASDAQ:...

CORT Investors Notified of Investigation Into Corcept Therapeutics, Inc. by Kaplan Fox

February 23, 2026

Biopharma company Corcept Therapeutics (NASDAQ:CORT) will be announcing earnings results this Tuesday afternoon. Here’s what to expect.

Corcept (CORT) Q4 Earnings: What To Expect

February 22, 2026

Via StockStory

Topics Artificial Intelligence World Trade

Kaplan Fox is Investigating Possible Securities Law Violations Against Corcept Therapeutics, Inc. (CORT)

February 21, 2026

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Kaplan Fox is Investigating Possible Securities Law Violations Against Corcept Therapeutics, Inc. (CORT)

February 21, 2026

NEW YORK, NY - February 21, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Corcept Therapeutics, Inc. (“Corcept” or the “Company”) (NASDAQ:...

Investor Alert: Robbins LLP Informs Investors of the Corcept Therapeutics Inc. Class Action Lawsuit

February 20, 2026

From Robbins LLP

Kaplan Fox Reminds Investors of Corcept Therapeutics, Inc. (CORT) to an Investigation of Potential Securities Law Violations

February 20, 2026

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.